PeptiCov News
2 articles
growth-positive
Pepticom raises $2.6 million for PeptiCov, spin-off company combatting Covid-19
Pepticom, an AI peptide drug design company, has raised $2.6 million in funding to establish a company called PeptiCov. PeptiCov will use AI technology to design and develop novel peptide molecules to treat the SARS-Cov-2 virus responsible for Covid-19. The funding round was led by the Chartered Group. Pepticoms AI technology streamlines the process of discovering candidates for peptide-based drugs by filtering out the most suitable candidates based on properties such as solubility and permeability. The Chartered Groups Technology division has previously invested in Pepticom and believes in its application of AI for SARS-Cov-2 drug discovery. Pepticom was founded in 2011 and has raised a total of $7.6 million in funding.
Investment
growth-positive
Pepticom's New Spinout Company, PeptiCov, to Focus on COVID-19
Pepticom has raised $2.6 million to establish a company called PeptiCov, which will focus on developing treatments for the SARS-Cov-2 virus. PeptiCov will use Pepticoms AI technology to design and discover novel peptide molecules for the treatment of COVID-19. The funding round was led by the Chartered Group. Pepticoms AI technology streamlines the discovery of advanced peptide-based drug candidates and has already designed potential peptide drug candidates for the SARS-Cov-2 virus. PeptiCov will be responsible for further development of these peptides and will seek partnerships with pharma companies. The Chartered Group has previously invested in Pepticom and other Israeli deep tech companies.
InvestmentPartners
